MannKind (NASDAQ:MNKD) Price Target Lowered to $7.00 at Wells Fargo & Company

MannKind (NASDAQ:MNKD) had its price target decreased by Wells Fargo & Company from $8.00 to $7.00 in a research report report published on Friday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of MannKind in a research note on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of MannKind in a research report on Thursday, January 22nd. Wall Street Zen upgraded MannKind from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Leerink Partners initiated coverage on MannKind in a report on Thursday, November 13th. They set an “outperform” rating and a $7.00 price objective on the stock. Finally, Truist Financial set a $9.00 target price on shares of MannKind in a report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.21.

MannKind Stock Up 0.8%

NASDAQ MNKD traded up $0.03 during trading hours on Friday, hitting $3.27. The company’s stock had a trading volume of 3,816,768 shares, compared to its average volume of 5,131,020. MannKind has a twelve month low of $2.93 and a twelve month high of $6.51. The firm has a market capitalization of $1.00 billion, a P/E ratio of 32.65 and a beta of 0.84. The stock has a fifty day moving average of $5.61 and a 200 day moving average of $5.35.

MannKind (NASDAQ:MNKD) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04). MannKind had a net margin of 9.32% and a negative return on equity of 49.33%. The business had revenue of $111.96 million for the quarter, compared to the consensus estimate of $99.85 million. During the same quarter in the previous year, the firm posted $0.03 EPS. The business’s revenue was up 45.8% on a year-over-year basis. On average, analysts predict that MannKind will post 0.1 earnings per share for the current year.

Insider Activity at MannKind

In other news, CEO Michael Castagna sold 107,920 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $5.57, for a total transaction of $601,114.40. Following the sale, the chief executive officer owned 2,504,792 shares in the company, valued at $13,951,691.44. This represents a 4.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Stuart A. Tross sold 47,006 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total transaction of $297,547.98. Following the transaction, the insider owned 985,007 shares in the company, valued at approximately $6,235,094.31. The trade was a 4.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 262,846 shares of company stock valued at $1,546,840 over the last three months. Insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On MannKind

Institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP acquired a new stake in shares of MannKind in the third quarter valued at approximately $61,297,000. Frazier Life Sciences Management L.P. bought a new stake in MannKind in the 4th quarter valued at $23,956,000. State Street Corp lifted its holdings in MannKind by 36.2% during the 4th quarter. State Street Corp now owns 14,623,269 shares of the biopharmaceutical company’s stock valued at $82,914,000 after purchasing an additional 3,883,071 shares during the last quarter. UBS Group AG boosted its position in MannKind by 146.7% during the third quarter. UBS Group AG now owns 5,194,739 shares of the biopharmaceutical company’s stock worth $27,896,000 after purchasing an additional 3,088,820 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of MannKind by 316.2% in the third quarter. Wellington Management Group LLP now owns 3,467,721 shares of the biopharmaceutical company’s stock valued at $18,622,000 after purchasing an additional 2,634,533 shares during the last quarter. Institutional investors and hedge funds own 49.55% of the company’s stock.

Key MannKind News

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Large bullish options activity was reported, suggesting speculative/hedged buying interest that can support near‑term upside. Read More.
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and $11.00 price target, a substantially higher long‑term upside projection that can attract growth‑oriented investors. Read More.
• Positive Sentiment: Company update highlights a modeled $450M 2026 revenue run rate and preparations for an Afrezza pediatric launch — clear product/catalyst milestones that underpin revenue growth expectations. Read More.
• Positive Sentiment: Q4 revenue of ~$112M beat consensus and grew ~46% year‑over‑year (Furoscix sales showed strong growth), supporting the company’s revenue momentum narrative. Read More.
• Neutral Sentiment: Royal Bank of Canada reaffirmed a “sector perform” rating with a $3.50 price target — a modestly supportive but cautious view that implies limited near‑term upside from current levels. Read More.
• Neutral Sentiment: Company filed earnings materials, slide deck and earnings‑call transcript (useful for investors doing deeper diligence on guidance, margins and product timelines). Read More. · Read More.
• Negative Sentiment: EPS missed expectations (reported loss $0.05 vs. consensus loss of $0.01) and the company posted an unexpected quarterly loss, which pressured sentiment and valuation multiples. Read More.
• Negative Sentiment: Market commentary flagged the earnings miss as the reason for a sell‑off and volatility; analysts and traders focused on the bottom‑line deterioration despite top‑line strength. Read More.
• Negative Sentiment: Shares hit a 52‑week low on the earnings reaction, indicating weak near‑term technical momentum and increased downside risk for short‑term traders. Read More.
• Negative Sentiment: Competitive pressure reported — United Therapeutics weighing a new treprostinil formulation — has added sector‑specific risk that could weigh on partner/product expectations. Read More.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.